4-Pentenamide, 5-chloro-N,N-dimethyl-2-(1-methylethyl)-, (2S,4E)- | CAS:324519-68-8

We serve 4-Pentenamide, 5-chloro-N,N-dimethyl-2-(1-methylethyl)-, (2S,4E)- CAS:324519-68-8 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
4-Pentenamide, 5-chloro-N,N-dimethyl-2-(1-methylethyl)-, (2S,4E)-

Chemical Name:4-Pentenamide, 5-chloro-N,N-dimethyl-2-(1-methylethyl)-, (2S,4E)-
CAS.NO:324519-68-8
Synonyms:
(E)-(S)-5-chloro-2-isopropyl-pent-4-enoic acid dimethylamide
(S,E)-5-chloro-2-isopropyl-N,N-dimethylpent-4-enamide
(2S,4E)-5-chloro-2-isopropyl-N,N-dimethylpent-4-enamide
Aliskiren inter-4
(2S,4E)-5-Chloro-N,N-dimethyl-2-(1-methylethyl)-4-pentenamide;
4-Pentenamide,5-chloro-N,N-dimethyl-2-(1-methylethyl)-,(2S,4E)
5-Chloro-2-isopropyl-pent-4-enoic acid dimethylamide

Molecular Formula:C10H18ClNO
Molecular Weight:203.70900

Physical and Chemical Properties:
Density: 0.999
Boiling point: 277ºCat 760mmHg
Melting point: /
Flash point: 121ºC
Refractive index: 1.471

Specification:
Appearance:White powder
Purity:≥98%

Packing:
 25kg  cardboard drum or according to customer specified requirements
Storage:Stored in a cool and dry well-closed container. Keep away from moisture and strong light/heat.
Application:Intermediates of Aliskiren CAS:173334-57-1
Intermediates of Aliskiren hemifumarate CAS:173334-58-2



Contact us for information like 4-Pentenamide, 5-chloro-N,N-dimethyl-2-(1-methylethyl)-, (2S,4E)- chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,5-Chloro-2-isopropyl-pent-4-enoic acid dimethylamide physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,(E)-(S)-5-chloro-2-isopropyl-pent-4-enoic acid dimethylamide Use and application,4-Pentenamide, 5-chloro-N,N-dimethyl-2-(1-methylethyl)-, (2S,4E)- technical grade,usp/ep/jp grade.


Related News: However, in the long run, as the bulk API market continues to fall, more and more companies will transition to specialty API companies, and competition will intensify in the future.2-Hydroxy-3-methoxy-3,3-diphenylpropanoic acid manufacturer However, in the long run, as the bulk API market continues to fall, more and more companies will transition to specialty API companies, and competition will intensify in the future.N-(4-(naphthalen-1-yl)phenyl)-[1,1'-biphenyl]-4-amine supplier “We believe the iLet Bionics Pancreas System represents a true breakthrough therapy for the management of glycemia, particularly in type 1 diabetes,” said Ed Damiano, President and CEO of Beta Bionics. “We are partuclarly excited by the possibility that the iLet may be able to provide safer and more effective therapy in far more people than current therapies due to its simplicity of use.”2-Bromoethanol vendor The US National Institutes of Health is working on a preventative vaccine, but it will likely take a few months until the first phase of clinical trials get underway, and more than a year until a vaccine might be available, according to experts.The US National Institutes of Health is working on a preventative vaccine, but it will likely take a few months until the first phase of clinical trials get underway, and more than a year until a vaccine might be available, according to experts.